Agreement Terms and Financial Considerations
Under the agreement, Sentynl Therapeutics receives the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the United States. Mereo BioPharma will retain commercial rights in the rest of the world. Sentynl also gains global rights to manufacture alvelestat for AATD-LD.
Mereo BioPharma will receive a non-refundable option fee from Sentynl. Upon exercise of the option, Mereo would be eligible to receive up to $40 million in upfront and R&D payments until New Drug Application (NDA) filing. Additionally, Mereo would receive double-digit tiered royalties on U.S. net sales of alvelestat.
Development and Regulatory Strategy
Mereo BioPharma will lead the global Phase 3 study and regulatory interactions until the study is completed. The companies will collaborate during the option period to advance manufacturing and refine the Phase 3 study design. The Phase 3 development program could be initiated in early 2027.
Alvelestat has received Orphan Drug Designation for AATD-LD from both the European Commission and the U.S. FDA, and has also received Fast Track designation from the FDA.
Product and Disease Background
Alvelestat is a novel, oral small molecule neutrophil elastase inhibitor being readied for Phase 3 development. If approved, it would be the first oral treatment for AATD-LD, a rare, progressive genetic lung disease affecting an estimated 50,000-80,000 individuals in the United States.
The safety and tolerability profile of alvelestat has been established through clinical trials in over 1,000 patients with various respiratory diseases, including AATD-LD, COPD, bronchiectasis, cystic fibrosis, COVID-19, and bronchiolitis obliterans syndrome.
Strategic Rationale
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, stated that the partnership marks a pivotal moment for Sentynl's rare disease strategy and expands their portfolio with a highly promising candidate that addresses significant unmet need.
Matt Heck, CEO of Sentynl Therapeutics, emphasized the opportunity to improve upon the current standard of care for AATD-LD patients, which often relies on generalized therapies or frequent intravenous treatments.
Denise Scots-Knight, CEO of Mereo BioPharma, noted that Sentynl's commitment to rare diseases and established commercial infrastructure make them an ideal partner for alvelestat.
Regulatory Filing Reference
The disclosure was made to the stock exchanges (BSE Limited and National Stock Exchange of India Limited) by Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited, on August 11, 2026.